Shares of Cadila Healthcare, the company’s listed entity, were trading 0.54% down at Rs404.75 apiece on BSE. Photo: company websiteNew Delhi: Drug firm Zydus Cadila on Wednesday said it has received final approval from US health regulator to market Dexmedetomidine Hydrochloride injection used for sedation of intubated and mechanically ventilated patients. The approval from US Food and Drug Administration (USFDA) is to market Dexmedetomidine Hydrochloride injection 200mcg (base)/ 2ML and 100mcg (base)/ ML single dose virals, Zydus Cadila said in a regulatory filing. The injection will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad. Shares of Cadila Healthcare, the company’s listed entity, were trading 0.54% down at Rs404.75 apiece on BSE.

Source: Mint February 28, 2018 10:30 UTC